StockData

Caribou Biosciences vs Fate Therapeutics

CRBU and FATE side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How CRBU and FATE compare

Fate Therapeutics is the larger company, worth 3.3 times as much as Caribou Biosciences ($122M against $36.5M).

Caribou Biosciences grew revenue faster over the last twelve months (10.0% versus −23.4% for Fate Therapeutics).

Caribou Biosciences keeps more of each dollar of sales as profit, with a net margin of −1030% compared with −1941% at Fate Therapeutics.

Caribou Biosciences scores higher on the StockData Score (9 against 8 for Fate Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricCRBUFATE
Size and price
Market cap$36.5M$122M
Share price$0.341$1.02
Change, 1 year−82.9%5.8%
Change, 5 years−98.1%−98.1%
Beta (5Y)1.413.98
Employees97161
StockData Score
Total score9 (better)8
Valuation score33
Growth score1 (better)0
Performance score00
Health score55
Dividend score00
Valuation
P/S3.6× (better)18.8×
P/B0.4× (better)0.8×
FCF yield−262%−86.4% (better)
Fair value$1.29$1.34
Margin of safety73.7% (better)23.8%
Growth
Revenue growth (TTM)10.0% (better)−23.4%
Revenue growth, 5Y average−2.0% (better)−26.7%
Profitability
Operating margin−1091% (better)−2058%
Net margin−1030% (better)−1941%
FCF margin−954% (better)−1627%
Return on equity−78.3%−60.7% (better)
Return on invested capital–−553%
Financial health
Debt / equity0.000.00
Current ratio6.49 (better)4.85
Altman Z-score−7.47 (better)−8.99
Piotroski F-score23 (better)
Dividends and buybacks
Buyback yield−66.3%–
Shareholder yield−66.3%0.00% (better)
Ownership
Held by institutions45.5%59.9%
Held by insiders5.7%25.7%
Insider net buying, 12 months−$47.5K (better)−$336K
Short interest, % of float14.7%11.2%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.